ADRB1 and head and neck cancer: Conversely, pancreatic and head/neck cancers showed detrimental outcomes (HR=1.70-1.82), potentially due to their β1-AR dominance (60-75% of cases) which may trigger compensatory EGFR activation when blocked, compounded by dense stromal barriers limiting drug penetration.